Form 4: Crinetics Officer Sells Shares After Option Exercise

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, Inc. (CRNX), engaged in transactions on November 3, 2025.
• Pizzuti exercised options to acquire 5,000 shares of common stock at an exercise price of $16.89 per share.
• Following the exercise, Pizzuti sold a total of 5,000 shares of common stock.
• 4,900 shares were sold at a volume-weighted average price of $42.65 per share, with prices ranging from $42.14 to $43.09.
• An additional 100 shares were sold at a price of $43.27 per share.
• These sales were conducted automatically pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
• After these transactions, Dana Pizzuti directly beneficially owns 66,270 shares of Crinetics Pharmaceuticals common stock.
• Pizzuti also holds 74,042 derivative securities (stock options) with an exercise price of $16.89, which vested 25% on September 30, 2023, and continue to vest monthly.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan. While an insider sale could be seen as slightly negative, the pre-planned nature and the fact that it's often for liquidity or diversification purposes makes it a neutral event in this context.

Positives

• The officer exercised options at a significantly lower price ($16.89) than the market sale price (average $42.65 $43.27), indicating a substantial personal gain.
• The transactions were executed under a Rule 10b5-1 trading plan, suggesting pre-planned activity rather than a reaction to immediate news.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces their direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine insider transactions under a pre-arranged plan. The sale might be perceived as a slight negative, but the pre-planned nature mitigates this.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine insider transaction involving an option exercise and subsequent sale under a Rule 10b5-1 plan. This type of transaction is generally pre-scheduled and not indicative of new material information about the company's performance or prospects. Therefore, it does not provide a basis for a change in investment recommendation; a "Hold" stance is appropriate as this filing alone does not alter the fundamental investment thesis for Crinetics Pharmaceuticals.

Keywords

Crinetics Pharmaceuticals, CRNX, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Dana Pizzuti, 10b5-1 Plan, Officer Transaction